An article published on The Lancet states that losing body weight can have a disease-modifying effect in people with type 2 diabetes.
The article, presented at the Annual Meeting of the European Association for the Study of Diabetes (EASD) congress, asserts that one of the metabolic complications of Obesity is type 2 diabetes, as the two conditions share key pathophysiological mechanisms.
Weight loss of 15% or more should become a central focus of managing type 2 diabetes (T2D), since it has the potential to improve glucose control, slow progress, reverse many cases and reduce complication.
The authors conclude: “The time is right to consider the addition of substantial (ie, double-digit %) weight loss as a principal target for the treatment of many patients with type 2 diabetes. This approach would address the pathophysiology of the disease process for type 2 diabetes; recognise adipose tissue pathology as a key underlying driver of the continuum of obesity, type 2 diabetes, and cardiovascular disease; and reap metabolic benefits far beyond blood sugar control. Such a change in treatment goals would recognise obesity as a disease with reversible complications and require a shift in clinical care.”
YOUNG50 project through the integration with other health-promoting programs, like implementing physical activity, healthy eating, healthy ageing, aims to work towards the improvement of many cardiovascular risk factors.
Know more about the YOUNG50 Project.
Reference: “Obesity management as a primary treatment goal for type 2 diabetes: time to reframe the conversation” by Prof Ildiko Lingvay, MD, Priya Sumithran, PhD, Ricardo V Cohen, MD and Prof Carel W le Roux, MD, 30 September 2021, The Lancet.